The Key Takeaways: Most common: Nausea (43%), manageable with dietary changes and timing Unique: Dysesthesia (20.9%), mild tingling sensations, not seen with Wegovy/Mounjaro Timeline: Worst during dose escalation (weeks 116), significant improvement after Discontinuation: 18.2% in TRIUMPH-4, 11.3% in TRIUMPH-1 the general obesity population tolerates it better than the osteoarthritis cohort Reversible: Stopping medication reverses side effects For most people with obesity especially severe obesity the 28.328.7% weight loss and associated health benefits outweigh the temporary discomfort during the first few months
However, improper usesuch as increasing the dosage too quicklycan reduce its effectiveness and lead to negative side effects
In early clinical trials, participants began with a starting dose of 2 mg per week , which was progressively increased over several weeks until reaching higher doses that demonstrated maximal therapeutic benefit
Each group benefits from transparent math that translates milligrams into practical syringe volumes
Industry Dynamics The rising geriatric population, which is at a higher risk of developing type 2 diabetes and related health conditions, has led to a greater need for GLP-1 analogues inhibitors